XBiotech Announces Dr. Alice Gottlieb to Chair Upcoming Phase 2 Study of Bermekimab in Hidradenitis Suppurativa
June 25 2019 - 8:45AM
XBiotech (NASDAQ: XBIT) announces that Alice Gottlieb M.D., Ph.D.,
will Chair the Company’s upcoming Phase II study in Hidradenitis
Suppurativa (HS). Dr. Gottlieb is Medical Director of dermatology
at the Mount Sinai Beth Israel Campus, and Clinical Professor at
the Icahn School of Medicine at Mount Sinai. She is one of few
doctors in the nation board certified in Dermatology, Rheumatology
and Internal Medicine. This will be the second study Chaired by Dr.
Gottlieb involving bermekimab in HS and the third study conducted
for the drug in HS.
Dr. Gottlieb received an M.D.-Ph.D. from The
Rockefeller University-Cornell University Medical College. Dr.
Gottlieb founded the Tufts Dermatology residency program (which
formally was shared with Boston University) and served as Chair of
Dermatology and Dermatologist-in-Chief of Tufts Medical Center. She
also founded the Dermatology Division at UMDNJ-Robert Wood Johnson
Medical School where she served as Professor of Medicine, Director
of the Clinical Research Center and Founding Director of the
Psoriasis Center of Excellence. Before joining the Mount Sinai
faculty, she was a Professor of Dermatology at New York Medical
College. She is the founder and President of the International
Dermatology Outcome Measures (IDEOM) group. Founded in 2013, this
501c3 non-profit, consortium of patients, physicians,
pharmaceutical scientists and other stakeholders is dedicated to
bringing outcome measures to dermatologic clinical research and
practice that satisfy the needs of all stakeholders.
Dr. Gottlieb is internationally recognized for
her pioneering work using targeted biological therapies, which
helped lead the way for FDA-approvals. Dr. Gottlieb has authored
over 400 manuscripts in leading scientific journals, such
as The Lancet and The New England Journal of Medicine and has
presented her groundbreaking research at hundreds of dermatology
and rheumatology conferences around the world. On June 7, 2018 she
was honored by an award from the National Psoriasis Foundation for
her leadership in psoriasis and psoriatic arthritis research and
care.
Dr. Gottlieb commented, “We need more effective
treatments for hidradenitis suppurativa. Bermekimab offers the
potential option for a more effective treatment for HS.”
XBiotech’s President & CEO, John Simard,
commented, “We are honored to have Dr. Gottlieb continue to advance
our bermekimab program in HS.”
Dr. Gottlieb chaired a recent open label study
with bermekimab that demonstrated that weekly treatment with
bermekimab was associated with statistically significant
improvement in HS, as measured by the Hidradenitis Suppurativa
Clinical Response score (HiSCR). In the study, 61% of patients with
no prior biological therapy achieved positive HiSCR at 12 weeks,
while 63% of patients who had failed previous biological therapy
also achieved a positive HiSCR. HS is associated with severe pain
and thus pain was a key measure in the study. At the study’s
endpoint, patients with no prior biological therapy had a 64%
reduction in pain compared with baseline, while those who had
previously failed anti-TNF therapy had a 54% reduction in pain.
Hidradenitis Suppurativa (HS) is a chronic,
inflammatory skin disorder affecting areas rich in apocrine glands.
Nodules appear in the affected areas and progressively become
swollen with spontaneous rupture and release of pus. This process
occurs repeatedly leading to formation of deep sinus tracts and
painful dermal abscesses. Pain is a paramount condition in patients
suffering from HS, as this chronic inflammation and accompanying
pain account for the fact that HS is ranked first among skin
disorders in terms of adversely affecting quality of life. The
global prevalence of HS is estimated at up to 4% of the
population.
About True Human™ Therapeutic
AntibodiesXBiotech’s True Human™ antibodies are derived
without modification from individuals who possess natural immunity
to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech’s True Human antibodies have the
potential to harness the body’s natural immunity to fight disease
with increased safety, efficacy and tolerability.
About XBiotech XBiotech is
a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of
therapeutic antibodies based on its True Human™ proprietary
technology. XBiotech currently is advancing a robust pipeline of
antibody therapies to redefine the standards of care in oncology,
inflammatory conditions and infectious diseases. Headquartered in
Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information, visit
www.xbiotech.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
ContactAshley
Oteroaotero@xbiotech.com512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024